- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00418639
Study of Nitazoxanide in the Treatment of Chronic Hepatitis C
January 3, 2007 updated by: Romark Laboratories L.C.
Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in the Treatment of Chronic Hepatitis C
This study will evaluate the effect of treatment with 24 weeks nitazoxanide monotherapy on end of treatment virologic response, sustained virologic response, reduction of quantitative serum HCV RNA, changes in ALT and safety parameters.
Study Overview
Study Type
Interventional
Enrollment
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alexandria, Egypt
- Department of Tropical Medicine & Infectious Diseases, Alexandria University
-
Cairo, Egypt
- Cairo Liver & GIT Center
-
Tanta, Egypt
- Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years.
- Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA.
- Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis.
Exclusion Criteria:
- Patients unable to take oral medications.
- Use of interferon alpha within 90 days or ribavirin within 30 days prior to enrollment.
- Females of child bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active.
- Any investigational drug therapy within 30 days prior to enrollment.
- Patients with other causes of liver disease.
- Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus based on enzyme immunoassay.
- Patients with history of alcoholism or with an alcohol consumption of >40 grams per day.
- Patients who are clinically unstable.
- Patients with any concomitant condition that, in the opinion of the investigator would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed.
- History of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Virologic response
|
Secondary Outcome Measures
Outcome Measure |
---|
Sustained virologic response
|
Quantitative serum HCV RNA
|
Changes in ALT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Samir M Kabil, MD, Cairo Liver & GIT Center
- Principal Investigator: Yehia El-Gohary, MD, Department of Tropical Medicine & Infectious Diseases, Alexandria University
- Principal Investigator: Asem Elfert, MD, Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2005
Primary Completion
December 7, 2022
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
January 3, 2007
First Submitted That Met QC Criteria
January 3, 2007
First Posted (Estimate)
January 5, 2007
Study Record Updates
Last Update Posted (Estimate)
January 5, 2007
Last Update Submitted That Met QC Criteria
January 3, 2007
Last Verified
January 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis, Chronic
- Hepatitis C, Chronic
- Anti-Infective Agents
- Antiparasitic Agents
- Nitazoxanide
Other Study ID Numbers
- RM01-3027
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hospices Civils de LyonCompleted
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States, Puerto Rico
Clinical Trials on Nitazoxanide
-
Telethon Kids InstituteWithdrawn
-
Azidus BrasilFarmoquimica S.A.; Hospital Vera Cruz; Hospital Casa de Saúde - Vera Cruz - Campinas... and other collaboratorsCompleted
-
Romark Laboratories L.C.CompletedRotavirus Infection | Norovirus Infection | Adenoviridae Infection
-
Azidus BrasilFarmoquimica S.A.Recruiting
-
Pinnacle Clinical Research, PLLCCompletedFatty Liver | Fibrosis, Liver | Compensated Cirrhosis | Non-alcoholic SteatohepatitisUnited States
-
Romark Laboratories L.C.CompletedRhinovirus | EnterovirusUnited States, Puerto Rico
-
Maha TalaabCompleted
-
Materno-Perinatal Hospital of the State of MexicoLaboratorios LiomontCompletedCoronavirus InfectionMexico
-
International Centre for Diarrhoeal Disease Research...University of VirginiaCompleted
-
Sadat City UniversityRecruitingIrritable Bowel Syndrome With DiarrheaEgypt